Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
在接受阿特珠单抗联合贝伐珠单抗治疗的晚期 BCLC C 期肝细胞癌患者中，第二疗程开始时血清 CXCL10 水平可预测治疗效果：一项多中心分析
期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.6876
Suzuki Takanori, Matsuura Kentaro, Suzuki Yuta, Okumura Fumihiro, Nagura Yoshihito, Sobue Satoshi, Matoya Sho, Miyaki Tomokatsu, Kimura Yoshihide, Kusakabe Atsunori, Narahara Satoshi, Tokunaga Takayuki, Nagaoka Katsuya, Kuroyanagi Keita, Kawamura Hayato, Kuno Kayoko, Fujiwara Kei, Nojiri Shunsuke, Kataoka Hiromi, Tanaka Yasuhito
